E1: reporter phone number was not available.Manufacturer's investigation conclusion: the report of suspected pump thrombus could not be confirmed through this evaluation.Additionally, analysis of the submitted log files confirmed elevated pump power and estimated flow values; however, a specific cause for this finding could not be conclusively determined.The submitted log files contained events from 04jan2024 through 04feb2024.Elevated pump power and estimated flow values were captured on 18jan2024.No other notable events or alarms were captured.The pump appeared to function as intended at the fixed speed.Multiple attempts were made to obtain additional information from the customer regarding the event; however, no additional information was provided.The device was not returned for evaluation.The relevant sections of the device history records for (b)(6) were reviewed and showed no deviations from manufacturing or quality assurance specifications.The heartmate ii lvas instructions for use (ifu) is currently available.Section 1 of the ifu, ¿introduction¿, lists potential adverse events, including device thrombosis and death, that may be associated with the use of the heartmate 3 left ventricular assist system.The hmii lvas ifu contains information regarding pump speed, power, flow, and pulsatility index (pi).The ifu explains that pump power is a direct measurement of motor voltage and current; therefore, changes in pump speed, flow, or physiological demand can affect pump power.Abrupt changes in power should be evaluated for cause.This document also describes how pump performance is sensitive to changes in systemic vascular resistance and left ventricular filling.Additionally, section 6 "patient care and management" outlines the recommended anticoagulation therapy and inr range.This section also outlines indications of pump thrombosis, as well as how to respond to such events.No further information was provided.The manufacturer is closing the file on this event.
|